Compare Entegris Inc (ENTG) vs Oruka Therapeutics Inc. Common Stock (ORKA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs Oruka Therapeutics Inc. Common Stock — how do they compare? Entegris Inc trades at $145.48 (market cap $23.39B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.08B). The key difference: Entegris Inc is far larger — about 4.6× Oruka Therapeutics Inc. Common Stock's market cap, and Entegris Inc pays a 0.26% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Entegris Inc for 41 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| ENTG | ORKA | |
|---|---|---|
Market Cap | $23.39B | $5.08B |
Volume | 2,918,074 | 685,276 |
Sector | Technology | Health |
52-Week High | $184.00 | $113.08 |
52-Week Low | $68.80 | $26.19 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | $26.60B | $4.21B |
Dividend Yield | 0.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENTG trades at $161.16, up 0.72% today, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results anticipated. Revenue remains stable around $3.2 billion, while profitability metrics show improvement, though valuation ratios like a P/E of 80.58 appear elevated. Positive sentiment is driven by AI-related semiconductor demand and recent institutional buying.
The outlook is positive given earnings momentum and sector tailwinds, but high valuation and competitive pressures pose risks. Upside to the $186.56 consensus price target depends on continued execution and market conditions.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →
